Treatment Study for Patients with Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Clinical Trial Title

Pazopanib neoadjuvant trial in non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

To identify the dose of pazopanib that is feasible when given in combination with radiation or chemo-radiation in pediatric and adult patients with unresected intermediate- and high-risk NRSTS.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are older than 2 years of age at the time of the biopsy that established the diagnosis  of NRSTS.
  • Have been newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk. Patients will be eligible for the chemotherapy or non-chemotherapy cohort based on:
    • Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials.
    • Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Rush Cancer Center Clinical Trials Office


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more